<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>HYPOTHESIS: Symptom control does not reflect elimination of abnormal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> or abnormal <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> in patients with long-segment <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> receiving <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Prospective survey </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: University hospital </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: Thirty-two patients with long-segment <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> who were asymptomatic with <z:chebi fb="4" ids="53266">PPIs</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>MAIN OUTCOME MEASURES: Twenty-four-hour ambulatory pH and <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> monitoring while continuing <z:chebi fb="4" ids="53266">PPIs</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Abnormal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> (pH &lt;4 for 11.9% [interquartile range, 6.8%-19.6%) of 24 hours] persisted in 15 patients (47%) who could not be distinguished from those with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> (pH &lt;4 for &lt;4.5% of 24 hours) by any endoscopic, manometric, or therapeutic characteristic </plain></SENT>
<SENT sid="6" pm="."><plain>Abnormal <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> (absorbance &gt;0.14 for 8.7% [interquartile range, 3.9%-8.7%] of 24 hours) was detected in 11 (48%) of 23 patients, such that both <z:mpath ids='MPATH_458'>normal</z:mpath> <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> (absorbance &gt;0.14 for &lt;1.8% of 24 hours) and <z:mpath ids='MPATH_458'>normal</z:mpath> <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> were observed in only 8 patients (35%) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no association between abnormal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> and abnormal <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Despite symptom control with <z:chebi fb="4" ids="53266">PPIs</z:chebi>, both <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> and <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> were controlled in only one third of patients </plain></SENT>
<SENT sid="9" pm="."><plain>Posttherapeutic monitoring of acid and <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> is recommended in future clinical trials of <z:chebi fb="4" ids="53266">PPI</z:chebi> treatment vs laparoscopic antireflux surgery </plain></SENT>
</text></document>